Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04976478
Other study ID # ChiECRCT20210238
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 2021
Est. completion date December 2026

Study information

Verified date July 2021
Source Peking University Third Hospital
Contact Junjie Wang, MD
Phone 010-82266699
Email junjiewang_edu@sina.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma


Description:

This is a perspective, multi-center, open-label and single arm study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 125
Est. completion date December 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender Female
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Age=65 years old 2. Histologically confirmed primary cervical squamous cell carcinoma in stage IB3-IVA (FIGO 2018) 3. At least one measurable lesion according to RECIST 1.1 guideline 4. Patients are intolerant to or refuse chemotherapy. 5. No serious hematopoietic dysfunction, nor abnormal heart, lung, liver and kidney function, nor immunity deficiency. And the results of lab test meet the following criteria: Hemoglobin =90g/L Absolute count of neutrophils=2×109/L orwhite blood cell count=4.0×109/L; Platelet count=100×109/L; AST=2.5×ULN ALT=2.5×ULN TBIL=1.5×ULN; Serum creatinine=1.5×ULN or CrCl> 60 mL/min(according toCockcroft-Gault): Serum creatinine=1.5×ULN Female CrCl=(140-Age)×Weight(kg)×0.85 / (72×Scr mg/dl) 6. ECOG score 0-2 7. Expectancy of life is at least 3 months. 8. Eligible for pelvic MRI examination. 9. The patients voluntarily received nimotuzumab combined with radiotherapy. 10. Patients can comply with the protocol and are willing to sign informed consent. Exclusion Criteria: 1. Patients who have received treatment for cervical cancer, including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy 2. Patients who have bilateral ureteral obstruction, who cannot be placed ureteral stents or perform pyelostomy. 3. Patients with rectovaginal fistula/vaginovesical fistula/uncontrolled vaginal bleeding or with fistula risk. .4)Patients infected with HIV. 5)Active hepatitis B (HBV DNA quantitative test results exceed the detection threshold), or HCV infection (HCV RNA quantitative test results exceed the detection threshold) 6)Patients with severe underlying disease that makes it possible to safely receive the treatment. And the severe underlying disease include but not limited to active infections requiring systemic medication, decompensated heart failure (NYHA grade III and IV), unstable angina pectoris, and acute myocardial infarction occurred within the first 3 months of enrollment. 7)Patients with a history of prior malignancy other than cured basal cell carcinoma of the skin. 8)Patients with Crohn's disease and ulcerative colitis. 9)Patients are allergic to Nimotuzumab or its compounds. 10)Patients with neurological or psychiatric abnormalities that affect cognitive ability. 11)Intracavitary brachytherapy cannot be performed that was assessed by the investigator. 12)Other factors were assessed by investigators to be unsuitable to this study.

Study Design


Intervention

Drug:
Nimotuzumab
Patients receive Nimotuzumab: 200mg, intravenous infusion, weekly for 6 weeks.
Radiation:
EBRT combined with brachytherapy
IMRT/VMAT are adopted. A total dose of 45-50.4 Gy, 1.8~2.0Gy/f, 25~ 28F in pelvic and/or extension filed. For patients with metastasis in pelvic lymph node and abdominal para-aortic lymph node, the dose of radiation in local lesion will be increased to 60~66Gy. For patients at stage IIIB, concurrent radiation will be given in parametrial extension or in the late course the dose will be increased to 60Gy. Brachytherapy: Three dimensional high dose rate brachytherapy is used with HR-CTV D90 cumulative dose of 80~85Gy (EQD2); If the tumor diameter is =4cm, HR-CTV D90 cumulative dose is =87Gy (EQD2). Brachytherapy combined with external beam radiotherapy will be completed within 8 weeks.

Locations

Country Name City State
China Peking University 3rd Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3-year disease-free survival(DFS) The rate of patient without disease in 3 years after treatment up to 3 years
Secondary Complete response rate(CRR) The percentage of subjects who achieve complete response by imaging assessment from the end of the treatment to disease progression 3 months later after treatment
Secondary Objective response rate(ORR) The percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment 3 months later treatment
Secondary 3-year overall survival(OS) The rate of patient alive in 3 years after treatment up to 3 years
Secondary The change of tumor related markers the correlation of the value of SCC,Cyfra 21-1 and therapeutic effect [The changes of serum tumor markers (such as SCC-Ag and CYFRA21-1) were observed before and after treatment] up to 3 years
Secondary The change of cervical tumor the change of the volume of the cervical tumor at diagnosis and before brachytherapy At diagnosis and before brachytherapy
Secondary QUALITY OF LIFE(QoL) Quality of life assessed by EORTC QLQ-CX 24 [EORTC QLQ-CX 24 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 24 items] up to 3 years
Secondary SAFETY Including severity of adverse events, the incidence of adverse events and serious adverse events. Adverse events should be reported and graded according to CTCAE version 5.0 up to 3 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05013268 - Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma Phase 1
Completed NCT02562729 - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Completed NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Phase 1/Phase 2
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Completed NCT01759355 - Hybrid PET/MR in the Therapy of Cervical Cancer
Completed NCT00068549 - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Phase 1
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00559377 - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Phase 2
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02466971 - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Phase 3
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Completed NCT00031993 - Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Phase 2
Active, not recruiting NCT01649089 - Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer N/A
Completed NCT00499031 - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Terminated NCT00070317 - Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer N/A
Active, not recruiting NCT03738228 - Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Phase 1